Salamanca Press

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "C...

NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medic...

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medica...

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medica...

NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medic...

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternativ...

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "C...

NEW YORK , March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medica...

NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medical...